Rheumatoid Arthritis With Adequate Bone QualityNCT03372278
PMCF Study on the Safety and Performance of the Zimmer® Maxera™ Acetabular System in Total Hip Arthroplasty
An observational study of Rheumatoid Arthritis With Adequate Bone Quality and Inflammatory Arthritis, run by Zimmer Biomet at 8 sites in 8 countries.
Trial summary
This study is a multicenter, prospective, non-controlled post market clinical follow-up study. The objectives of this study are to confirm the safety and performance of the commercially available Zimmer® Maxera™ Acetabular System in Total Hip Arthroplasty. Read more about this study
- Who is it for?
- Ages 18 to 75 years
- Conditions the study is for
- Rheumatoid Arthritis With Adequate Bone Quality, Inflammatory Arthritis, Osteoarthritis, Hip
- How many people
- 250 participants
- Where
- 8 sitesin 8 countries
- Study dates
- Jan 2013to Dec 2028
- Phase
- Observational
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 75 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients suffering from severe hip pain and disability requiring total hip arthroplasty and who meet the inclusion/exclusion criteria
Who may be able to join
- Patient is 18 to 75 years of age, inclusive.
- Patient is skeletally mature.
- Patient qualifies for primary unilateral or simultaneous bilateral total hip arthroplasty (THA) based on physical exam and medical history including at least one of the following:
- Osteoarthritis
- Avascular necrosis (AVN)
- Inflammatory arthritis
Show all 14Show fewer
- Rheumatoid arthritis with adequate bone quality
- Post-traumatic arthritis
- Congenital hip dysplasia.
- Patient has no history of previous total hip replacement or arthrodesis of the affected hip joint(s). Patient has a Harris Hip Score <70 in the affected hip and a Harris Hip pain rating of moderate, marked, or disabled.
- Patient is willing and able to provide written informed consent.
- Patient is willing and able to cooperate in the required post-operative therapy.
- Patient is willing and able to complete scheduled follow-up evaluations as described in the Informed Consent.
- Patient has participated in the Informed Consent process and has signed the Ethics Committee approved informed consent.
Who cannot join
- The patient is:
- A prisoner
- Mentally incompetent or unable to understand what participation in the study entails.
- A known alcohol or drug abuser
- Anticipated to be non-compliant
- The patient has a neuromuscular disorder, vascular disorder or other condition that could contribute to prosthesis instability, prosthesis fixation failure, or complications in postoperative care.
Show all 29Show fewer
- The patient has local bone tumors and/or cysts in the portion of bone to be retained in the operative hip that could inhibit implant fixation.
- The patient has insufficient bone stock or poor bone quality to fix the component. Insufficient bone stock exists in the presence of metabolic bone disease (i.e. osteoporosis), cancer, and radiation. Note: Dual Energy X-ray Absorptiometry (DEXA) may be required to assess the presence of adequate bone stock.
- The patient has rapid disease progression as obvious by joint destruction or bone absorption seen on x-ray.
- The patient has osteoradionecrosis in the affected hip.
- The patient has a neuromuscular condition in the ipsilateral or contralateral limb which affects lower limb function.
- The patient has loss of abductor musculature in the affected hip.
- The patient has a vascular (large and small vessel disease) insufficiency.
- The patient has had previous prosthetic hip replacement device (any type, including surface replacement arthroplasty, endoprosthesis, etc.) in the joint to be operated.
- The patient has had previous girdlestone procedure (resection arthroplasty) or surgical fusion of the hip to be operated.
- The patient has an acute femoral neck fracture in the operative hip.
- The patient has had a procedure on the operative hip in the last 6 months (i.e. arthroscopy, ORIF femoral neck fracture, etc).
- The patient has undergone a total hip replacement, endoprosthesis, or surface arthroplasty of the contralateral (opposite side) hip within the past 6 months regardless of whether the previous hip was enrolled in this clinical study.
- The patient has a moderate to severe limb length discrepancy greater than 3.2 cm.
- The patient has an active, old or remote infection in or about the affected hip joint or an infection distant from the hip joint that may spread to the hip hematogenously.
- The patient has poor skin coverage around the affected hip joint.
- The patient has a diagnosed systemic disease that could affect his/her safety or the study outcome.
- The patient is currently receiving, or within the past three months, has received any drug known to potentially interfere with bone/soft tissue healing (e.g. long-term chronic systemic steroid or inhaler steroid therapy).
- The patient has received an investigational drug or device within the previous 6 months.
- The patient is known to be pregnant.
- The patient is unwilling or unable to give informed consent, or to comply with the followup program.
- The patient is known to have a highly communicable disease that may limit follow-up.
- The patient has a known sensitivity or allergic reaction to one or more of the implanted materials which include metal and ceramic.
- The patient is Grade III obese with a Body Mass Index (BMI) > 35.
Trial locations and contacts
8 sites in 8 countries.
8 sites in 8 countries
United Kingdom1 site
Royal Liverpool and Broadgreen University Teaching Hospitals
Liverpool
About this study
Official title: Zimmer® Maxera™ Acetabular System in Total Hip Arthroplasty. A Multicenter, Prospective, Non-controlled Post Market Clinical Follow-up Study
This study is a multicenter, prospective, non-controlled post market clinical follow-up study. The objectives of this study are to confirm the safety and performance of the commercially available Zimmer® Maxera™ Acetabular System in Total Hip Arthroplasty.
Read the detailed description
The objectives of this study are to confirm the safety and performance of the Zimmer Maxera Cup mated with either a BIOLOX® delta or BIOLOX® OPTION femoral head when used in primary total hip arthroplasty.
In total 250 patients will be enrolled into the study at up to 10 sites.All potential study subjects will be required to participate in the Informed Consent Process.
- Conditions
- Rheumatoid Arthritis With Adequate Bone Quality, Inflammatory Arthritis, Osteoarthritis, Hip, Avascular Necrosis, Post-traumatic; Arthrosis, Congenital Hip Dysplasia
- Keywords
- Total hip arthroplasty, Medical Device, Safety, Prothesis
- Medical subject headings
- Arthritis, Osteoarthritis, Hip, Osteonecrosis, Osteoarthritis, Hip Dislocation, Congenital
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Patients who received the Maxera Cup | Subjects in need of a total hip arthroplasty, who met the inclusion/exclusion criteria and who received the Maxera Cup. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Implant survival based on removal or intended removal of the device and determined using the Kaplan-Meier method
Measured: 10 years post-surgery
Secondary outcomes (5)
Pain and functional performance based on the Harris Hip Score
Measured: 10 years post-surgery
Pain and functional performance based on the UCLA Score
Measured: 10 years post-surgery
Subject quality-of-life determined by the EQ-5D (EuroQoI) score
Measured: 10 years post-surgery
X-rays evaluated for radiolucencies, osteolysis, hypertrophy, subsidence, heterotopic ossification, etc
Measured: 10 years post-surgery
Safety based on eventual complications occurred including dislocations and revisions/removals
Measured: 10 years post-surgery
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted13 Dec 2017
- Study startJan 2013
- Primary completionJan 2027 (estimated)
- Study completionDec 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Rheumatoid Arthritis With Adequate Bone QualityStudies of the same condition, open and under way.
- More trials run by Zimmer BiometThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 250 participants (actual)
Sponsor and investigators
- Lead sponsor
- Zimmer Biomet
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Hassan Achakri, Study director, Zimmer Biomet
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03372278
- Sponsor's protocol ID
- CIE2011-01H
- Status last verified
- Sep 2026
- First submitted
- 30 Nov 2017
- Last updated
- 29 Sep 2026
- Results posted
- No
- FDA-regulated drug
- No